Theratechnologies appoints new ceo
John-Michel Huss has more than 20 years’ experience in the pharmaceutical industry
Until recently, Huss was chief of staff, in the office of the ceo, at Sanofi-Aventis in Paris. He has more than 20 years’ experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism.
Huss began his career in 1990, at Merck & Co, primarily in sales and marketing in the US, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an internal product manager at its Basel headquarters in Switzerland. From there in 1999, he joined Sanofi-Synthélabo as business unit director and has held various positions of increasing responsibility in marketing and sales. He became general manager in Switzerland in 2007.
During his tenure at Sanofi-Aventis (Sanofi-Synthélabo merged with Aventis in 2004) Huss held positions in Germany, Canada, Switzerland and France.
‘I am honoured to have been chosen as Theratechnologies' president and ceo,’ said Huss.
‘The company has done an outstanding job of developing an exciting new compound, tesamorelin, and navigating it through the final regulatory stages of the drug development process.’
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things
Regulatory
Pheno Therapeutics secures two patents for neurological drug pipeline
The Edinburgh-based biotech has strengthened its intellectual property portfolio for two selective GPR17 antagonists, including its lead multiple sclerosis candidate, PTD802, which has US and UK regulatory clearance to enter clinical trials
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Cleaning
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects